Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
polyvalent allogeneic cell vaccine
- Development stage
- Preclinical
- Lead developer
- CancerVax
- Modality
- Vaccines & Immunotherapeutics, Cell Therapies
- Administration
- Intramuscular, Intradermal, Intratumoral
01
Overview
PACV (polyvalent allogeneic cell vaccine) is an active immunotherapy designed to treat recurrent metastatic melanoma. This vaccine aims to re-stimulate specific immune responses in patients, which has been correlated with improved survival following recurrence and adjuvant immunotherapy. It utilizes allogeneic cells, meaning cells from a donor, to present a broad range of antigens to the immune system, thereby eliciting a robust anti-tumor response.
Beyond the preview
Go deeper on polyvalent allogeneic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on polyvalent allogeneic cell vaccine.